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INTRODUCTION : 
Many prospective epidemiological studies have reported positive  
associations between the risk of cardiovascular disease  and plasma  
fibrinogen levels[1] Fibrinogen is the major coagulation protein in blood by  
mass, the precursor of fibrin, and an important determinant of blood viscosity  
and platelet aggregation.[2,3] Because fibrinogen levels can be reduced  
considerably by lifestyle interventions that also affect levels of established risk  
factors (such as regular exercise, smoking cessation, and moderate alcohol  
consumption), there is interest in the possibility that measurement (or  
modification) of fibrinogen may help in disease prediction or prevention[4].  
         Nevertheless, the relationship between hyperfibrinogenemia,  
atherosclerosis and thrombosis is complicated. As the process of  
thrombogenesis is very closely related to atheroma formation (atherogenesis),  
it follows that specific thrombogenic factors such as fibrinogen  may play key  
roles in the process of atherosclerotic lesion formation, with subsequent effects  
on cardiovascular diseases . However, knowledge about the precise  
determinants of plasma fibrinogen levels in health and disease is as yet  
incomplete, and many paradoxes are still present. For example, it is known that  
plasma fibrinogen is higher in Black than in White patients [5] but (in the UK at  
least) coronary artery disease is less common in Blacks than in White patients,  
while hypertension and stroke are conversely more common [6,7].  Plasma  
fibrinogen is also influenced by many factors: it increases with age, body mass  
index, smoking, diabetes and post menopause and is related to fasting serum  
insulin, low-density-lipoprotein (LDL) cholesterol lipoprotein(a) and leukocyte  
count. Conversely, it decreases with moderate alcohol intake, physical activity,  
increased high-density-lipoprotein (HDL) cholesterol, and with hormone  
replacement therapy [8,9,10] . 
 
Fibrinogen and fibrin structure and functions; 
 
Fibrinogen molecules are comprised of two sets of disulfide-bridged  
 
Aalpha-, Bbeta-, and gamma-chains. Each molecule contains two outer D  
 
domains connected to a central E domain by a coiled-coil segment. Fibrin is  
 
formed after thrombin cleavage of fibrinopeptide A (FPA) from fibrinogen  
 
Aalpha-chains, thus initiating fibrin polymerization. Double-stranded fibrils  
 
form through end-to-middle domain (D:E) associations, and concomitant  
 
lateral fibril associations and branching create a clot network. Fibrin assembly  
 facilitates intermolecular antiparallel C-terminal alignment of gamma-chain  
 
pairs, which are then covalently 'cross-linked' by factor XIII ('plasma  
 
protransglutaminase') or XIIIa to form 'gamma-dimers'. In addition to its  
 
primary role of providing scaffolding for the intravascular thrombus and also  
 
accounting for important clot viscoelastic properties, fibrin(ogen) participates  
 
in other biologic functions involving unique binding sites, some of which  
 
become exposed as a consequence of fibrin formation. This review provides  
 
details about fibrinogen and fibrin structure, and correlates this information  
 
with biological functions that include: (i) suppression of plasma factor XIII- 
 
mediated cross-linking activity in blood by binding the factor XIII A2B2  
 
complex. (ii) Non-substrate thrombin binding to fibrin, termed antithrombin I  
 
(AT-I), which down-regulates thrombin generation in clotting blood. (iii)  
 
Tissue-type plasminogen activator (tPA)-stimulated plasminogen activation by  
 
fibrin that results from formation of a ternary tPA-plasminogen-fibrin complex.  
 
Binding of inhibitors such as alpha2-antiplasmin, plasminogen activator  
 inhibitor-2, lipoprotein(a), or histidine-rich glycoprotein, impairs plasminogen  
 
activation. (iv) Enhanced interactions with the extracellular matrix by binding  
 
of fibronectin to fibrin(ogen). (v) Molecular and cellular interactions of fibrin  
 
beta15-42. This sequence binds to heparin and mediates platelet and  
 
endothelial cell spreading, fibroblast proliferation, and capillary tube  
 
formation. Interactions between beta15-42 and vascular endothelial (VE)- 
 
cadherin, an endothelial cell receptor, also promote capillary tube formation  
 
and angiogenesis. These activities are enhanced by binding of growth factors  
 
like fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor  
 
(VEGF), and cytokines like interleukin (IL)-1. (vi) Fibrinogen binding to the  
 
platelet alpha(IIb)beta3 receptor, which is important for incorporating  
 
platelets into a developing thrombus. (vii) Leukocyte binding to fibrin(ogen)  
 
via integrin alpha(M)beta2 (Mac-1), which is a high affinity receptor on  
 
stimulated monocytes and neutrophils [11]. 
 
  
 
 
 
 
 
 
AIM OF THE STUDY ; 
 
     Fibrinogen is a major determinant of plasma viscosity; an elevated 
 
fibrinogen level might also be associated with cardiovascular events. 
 
Whether the association between fibrinogen and cardiovascular events and  
 
whether fibrinogen predicts incidence of ischemic stroke is unclear. The aim  
 
of the study is to evaluate the fibrinogen levels in 50 patients with ischemic  
 
stroke and to determine the consistency of its association when compared  
 
with 50 patients without stroke as controls.  
 
 
 
 
REVIEW OF LITERATURE ; 
The associations between fibrinogen level and the incidence of a broad  
range of different chronic diseases are particularly striking, including not just  
major ischemic cardiovascular diseases but also the aggregate of nonvascular  
mortality [12,13].  The magnitude of the associations persisted largely  
unchanged in analyses restricted to never smokers and to disease cases  
recorded several years after the baseline examination, reducing the likelihood  
that they were mainly due to cigarette smoking habits and/or early  
cardiovascular disease. It has been suggested that such associations reflect a  
response to cumulative environmental stressors (as indicated by circulating  
levels of fibrinogen and other inflammatory factors), which may modify the  
risk, progression, and outcomes of various chronic diseases [14].  Although the  
lack of specificity in the associations of fibrinogen level with different vascular  
and nonvascular outcomes does not necessarily exclude a causative role for  
fibrinogen in ischemic cardiovascular diseases, there remains scope in these  
estimates for biases due to residual (or unmeasured) confounding by other  
factors. 
Pathophysiology ; 
Fibrinogen is a soluble glycoprotein found in the plasma, with a  
molecular weight of 340 kDa [15].  It comprises of three pairs of non-identical  
polypeptide chains (alpha, beta and gamma chains) [16] linked to each other  
by disulphide bonds. Fibrinogen has a biological half-life of about 100 h and is  
synthesized predominantly in the liver [17].  As a clotting factor, fibrinogen is  
an essential component of the blood coagulation system, being the precursor of  
fibrin. However, at the ‘usual’ plasma levels of 1.5 to 4.5 g/l, its concentration  
far exceeds the minimum concentration of 0.5–1 g/l necessary for  
haemostasis.  
Fibrinogen plays a vital role in a number of physiopathological processes  
in the body, including inflammation, atherogenesis and thrombogenesis.  
Nevertheless, our understanding of the mechanisms leading to the  
atherothrombogenic action of fibrinogen is fragmentary. Proposed mechanisms  
include the infiltration of the vessel wall by fibrinogen, haemorrheological  
effects due to increase in blood viscosity, increased platelet aggregation and  
thrombus formation. Furthermore, plasma fibrinogen is also a prominent acute- 
phase reactant. It augments the degranulation of platelets in response to  
adenosine diphosphate (ADP), when taken up by the granules. Thus, elevated  
concentrations of fibrinogen, perhaps secondary to inflammation or infection  
(Chlamydia pneumoniae  or Helicobacter pylori) implicated in cardiovascular  
risk may operate, in part, by increasing the reactivity of platelets.[18] 
Fibrinogen and inflammation ; 
 The process of inflammation is primarily mediated by its interaction with  
leucocytes through the surface receptors of the latter termed ‘integrins’. The 2  
main receptors for fibrinogen on the surface of leukocytes include Mac-1  
(CD11b/CD18, alpha M beta 2) and alpha X beta 2 (CD11c/CD18, p150, 95).  
Leukocytes (both monocytes and myelocytes) can specifically induce MAC–1  
receptor to bind fibrinogen [19,20]. The ability of MAC–1 receptor to bind  
fibrinogen results from the maturational changes occurring in the receptor  
during the process of cell differentiation, and is not seen in a resting leucocyte.  
The site on fibrinogen that interacts with MAC-1 is not shared by other  
integrins.[21] 
Fibrinogen is also a ligand for Intercellular Adhesion Molecule-1 (ICAM- 
1), and enhances monocyte-endothelial cell interaction by bridging the Mac-1  
on monocytes to ICAM-1 on endothelial cells.[22,23] Thus, ICAM-1 behaves as  
cell surface ligand for alpha L beta 2 and alpha M beta 2 (MAC-1) integrins, and  
has a key role in leukocyte adhesion to the vascular endothelium. Furthermore,  
fibrinogen upregulates and increases the concentration of ICAM-1 proteins on  
the surface of endothelial cells, resulting in increased adhesion of leukocytes  
on the surface of endothelial cells [24] ,even at high shear rates in flow  
conditions [25].  Moreover, the fibrinogen binding to ICAM-1 on the endothelial  
cells also mediates the adhesion of platelets. The interaction of fibrinogen and  
cells expressing ICAM-1 is associated with cellular proliferation [26]. 
Fibrinogen, on binding to its integrin receptor on the surface of  
leukocytes also facilitates a chemotactic response, thus playing a vital role in  
the process of inflammation [27].  One of the proposed mechanisms by which  
fibrinogen induces pro-inflammatory changes in leukocytes includes an  
increase in the free intracellular calcium and increased expression of neutrophil  
activation markers. These processes result in an increase in phagocytosis,  
antibody-mediated leucocyte toxicity and delay in apoptosis [28]. 
Fibrinogen is also involved in the facilitation of both cell–cell interaction  
and the interaction of cell and extracellular matrix such as collagen [19,29].   
Thus, as explained above, fibrinogen is an important mediator of cell–cell  
interaction, adhesion and inflammation.  
Finally, there is evidence that fibrinogen facilitates the biomaterial- 
provoked inflammatory response [30].  Interaction with the biomaterial results  
in conformational changes within the fibrinogen molecule and conversion into  
‘proinflammatory’ fibrinogen, resulting in the exposure of the epitope that  
interacts with the MAC-1 receptor for macrophages [30,31].  
Fibrinogen and atherogenesis ; 
There seems to be little doubt that fibrin deposition can both initiate  
atherogenesis and contribute to the growth of plaques [32,33].  Fibrinogen and  
its metabolites appear to cause endothelial damage and dysfunction by a  
number of mechanisms [34].  Many human atherosclerotic lesions, showing no  
evidence of fissure or ulceration, can contain a large amount of fibrin, which  
may either be in the form of mural thrombus on the intact surface of the  
plaque, in layers within the fibrous cap, in the lipid-rich core, or diffusely  
distributed throughout the plaque. This phenomenon may be compounded by  
the decrease in arterial intimal fibrinolytic activity and plasminogen  
concentration observed in cardiovascular disease [32]. 
It has been proposed that once in the arterial intima, fibrin stimulates  
cell proliferation by providing a scaffold along which cells migrate, and by  
binding fibronectin, which stimulates cell migration and adhesion [35]. 
 Fibrin degradation products, which are present in the intima, may stimulate  
mitogenesis and collagen synthesis, attract leukocytes, and alter endothelial  
permeability and vascular tone. In the advanced plaque, fibrin itself may be  
involved in the tight binding of LDL and accumulation of lipid, resulting in the  
lipid core of atherosclerotic lesions [32]. However, it cannot be  
overemphasized that many of these observations are only associations, and a  
definite causal role for fibrinogen cannot be fully demonstrated. 
Fibrinogen and thrombogenesis ; 
Thrombogenesis is regulated by a fine balance between the coagulation  
and fibrinolytic pathways. Subsequent to vessel wall trauma, tissue  
thromboplastin is released from the sub-endothelium. Tissue thromboplastin in  
turn triggers the extrinsic pathway of coagulation by activating factor VII to  
VIIa. Contact of blood with the foreign surface initiates the intrinsic pathway of  
coagulation, by activating factor XII to XIIa, as well as platelets. Platelet  
aggregation, however, does not confer adequate stability, and therefore  
activation of the coagulation pathway is also necessary. 
The final common pathway of the coagulation cascade involves the  
 
activation of factor X to Xa, and the subsequent activation of prothrombin to  
 
thrombin. Thrombin, which is a protease enzyme, facilitates the cleavage of  
 
fibrinogen into fibrin monomers, which link to each other both sideways and  
 
end-to-end to form fibrin polymers. Activated factor XIII facilitates the cross  
 
linkage of fibrin polymers to form a stable fibrin clot.  
Fibrinogen is also involved in the final common pathway of platelet  
aggregation. Fibrinogen cross-links the platelets by binding the glycoprotein  
IIb-IIIa receptor on the platelet surface [36].  This has become more relevant  
with the advent of glycoprotein IIb-IIIa receptor inhibitors, which block this  
final common pathway of platelet binding. 
Determinants of plasma fibrinogen levels; 
Factors associated with raised 
fibrinogen levels. 
Factors associated with lower 
fibrinogen levels. 
Advancing age Young age 
Female sex Male sex 
Black race Caucasians 
Smoking Cessation of smoking 
Obesity Weight reduction 
Physical inactivity Regular exercise 
Elevated cholesterol Moderate alcohol consumption 
Menopause Hormone replacement therapy 
Oral contraception  
Low socio-economic status  
Stress  
 
 
Plasma fibrinogen level is dependent upon both genetic and  
environmental factors.  
Genetic influences; 
The evidence suggests that plasma fibrinogen levels are probably under  
substantial genetic control, as genetic polymorphisms account for some 20– 
51% of variations in plasma fibrinogen levels [37,38]. The demonstration of  
such substantial genetic control further supports the view that plasma  
fibrinogen is a primary risk factor for atherothrombotic disorder rather than  
just a reflection of such disorder . 
The fibrinogen locus comprises three genes coding for fibrinogen gamma  
(FGG), fibrinogen alpha (FGA), and fibrinogen beta (FGB), clustered in a region  
of approximately 50 kb on the long arm of chromosome 4q23-q32, the  
direction of transcription of the ß gene being in the opposite direction to that of  
the other two [39]. There is a single copy of each gene; the gene in the middle  
flanked by the ß gene on one side and the gene on the other. Variation in the  
fibrinogen locus contributes to the individual differences in plasma fibrinogen  
levels [40].  However, the precise molecular mechanism(s) underlying the  
genetic heritability of plasma fibrinogen concentration remain unclear.  
The genetic influence on the fibrinogen beta-chain gene has been more  
extensively studied, because ß-chain synthesis is the limiting step in the  
production of mature fibrinogen [41].  In recent years, several polymorphisms  
have been identified in the fibrinogen chain genes that determine plasma levels  
of fibrinogen, mainly by restriction fragment length polymorphism (RFLP) and  
single-stranded conformation polymorphism (SSCP) analyses [40,42,43]. For  
example, the BclI RFLP of the ß fibrinogen gene is associated with between- 
person differences in plasma fibrinogen levels [44]. Similarly, van’t Hooft et  
al.[45] demonstrated that the -455G/A and -854G/A polymorphisms of the ß  
fibrinogen gene have a significant impact on the plasma fibrinogen  
concentration. The -455G/A mutation in the promoter region of the ß  
fibrinogen gene is one of the strongest genetic variations, associated with an  
increase in plasma fibrinogen in both genders in the general population [43,46] 
However, the results have been conflicting, and some studies have failed  
to demonstrate such relationships between these genetic polymorphisms and  
plasma fibrinogen levels. For example, Connor et al [47] found that plasma  
fibrinogen levels did not show any significant associations with the four  
fibrinogen polymorphisms examined, at the (TaqI), ß (BclI and HaeIII), and  
(KpnI/SacI) fibrinogen loci. Humphries et al. [37]  found that the individuals  
with the genotype B1B1 had a mean fibrinogen of 2.74 g/l, while those with  
B2B2 had a mean plasma fibrinogen level of 3.69 g/l, a level previously  
associated with a strongly increased risk of IHD. Those heterozygous for the  
two alleles, with the genotype B1B2, had mean plasma fibrinogen levels of  
2.98 g/l.  
Despite the recognition that plasma fibrinogen levels are under a  
‘significant’ degree of genetic control, the precise  genes/alleles/ 
polymorphisms that are responsible for the variation in levels between  
different populations, and the clinical significance, if any, still remains  
uncertain as much of the limited data are conflicting.  
Extrinsic influences ; 
There is evidence that plasma fibrinogen level and its associated  
cardiovascular risk may be dependent upon an interaction between  
environmental and intrinsic (genetic) factors rather than just the latter. For  
example, there is a dose-response effect between the number of cigarettes  
smoked and plasma fibrinogen level, as well as an inverse relationship with  
time since cessation of smoking [48]. Moderate drinking may lower plasma  
fibrinogen concentration, and if fibrinogen is a causal risk factor for  
cardiovascular disease, it may be one of the variables that explain the  
protective effect of moderate alcohol consumption on cardiovascular  
disease[49]. The observation of extrinsic influences on plasma fibrinogen levels  
suggests that elevated plasma fibrinogen levels may be modifiable through  
appropriate lifestyle changes. Furthermore, there is evidence that strategies 
that lower the cardiovascular risk may also lower plasma fibrinogen levels[50].   
 
Nonetheless, whether these measures translate to clinically relevant benefits  
 
remain uncertain, as the mediator(s) of the beneficial effects may be due to  
 
mechanisms (e.g. endothelial function, lipids, etc.), or combinations of  
 
mechanisms, other than the reduction of plasma fibrinogen per se. Some of the  
 
more important extrinsic influences on plasma fibrinogen levels are discussed  
 
below.  
Gender ; 
The second World Health Organization Monitoring Trends and  
Determinants in Cardiovascular Disease (MONICA) Augsburg survey found the  
crude fibrinogen values to be consistently higher in women than in men of all  
ages, irrespective of pregnancy or the use of oral contraceptives  
[51,52,53,54,55].  Plasma fibrinogen levels are higher in women than in men,  
even after accounting for confounding factors, as observed in the Goteborg  
MONICA survey. Furthermore, this pattern was observed even among healthy  
adolescents in the Florence Teenager Study [52]  However, occasional studies  
have failed to demonstrate a significant gender difference in plasma fibrinogen  
levels between men and women [53].  It should also be noted that amongst the  
prospective epidemiological studies, only the Framingham study included  
women; thus the influence of plasma fibrinogen on cardiovascular risk amongst  
women still needs to be more strongly established.  
Age ; 
Plasma concentrations of fibrinogen generally increase with age [56,57].  
This age-related increase in plasma fibrinogen may be due to a slower rate of  
disposal of fibrinogen, rather than an increased production rate [58].  
Body mass index and body habitus ; 
Plasma fibrinogen concentration has been positively correlated with body  
mass index, the waist circumference, the hip circumference and waist-to-hip  
ratio in both sexes [59]. Indeed, plasma fibrinogen level is significantly higher  
amongst patients with a body mass index of > 30 kg/m2, compared to those  
with body mass index < 25 kg/m2 [60], and rises with higher quartiles of skin  
fold thickness [61].  
Moreover, weight reduction can reduce plasma fibrinogen. For example,  
Ditschuneit et al [59]. reported that in patients who were extremely  
overweight and had high plasma fibrinogen levels, a reduction in weight (mean  
± SEM 20 ± 3 kg) correlated with a decrease in plasma fibrinogen levels (0.33  
± 0.1 g/l). Surgical treatment of morbid obesity may have a long-term  
beneficial effect on mortality from cardiovascular and thromboembolic disease,  
as demonstrated by the reduction of the decrease in prothrombotic factors,  
including fibrinogen [62]. In a study by Primrose et al [62].  haemostatic and  
fibrinolytic factors were measured before and again 6 and 12 months after  
surgery (vertical gastric stapling with or without jejuno-ileal bypass) in 19  
patients suffering from morbid obesity. This resulted in a mean decrease in  
body weight of 64 kg at 12 months, accompanied at 12 months by significant  
reductions in median concentrations of serum cholesterol (from 5.3 mmol/l to  
3.6 mmol/l); factor VII (from 113% of normal to 99%); fibrinogen (from 3.5  
g/l to 2.8 g/l); and plasminogen activator inhibitor-1 activity (from 21 IU/ml to  
6.3 IU/ml).  
Metabolic syndrome ; 
‘Metabolic syndrome’ is characterized by the presence of three or more of  
the following metabolic markers: high-density lipoprotein-cholesterol < 1.13  
mmol/l; triglycerides 1.80 mmol/l; glucose 5.5 mmol/l; diastolic blood  
pressure 90 mm Hg. Obesity, poor cardiorespiratory fitness and the metabolic  
syndrome are all closely linked to each other. Furthermore, these may be  
related to the development of haemorrheological abnormalities (such as  
increased fibrinogen) associated with the metabolic syndrome. Plasma  
fibrinogen increases with a number of components of the metabolic syndrome,  
independent of major confounders [63]. The age-adjusted OR for  
hyperfibrinogenaemia (  3.47 g/l) was non-significantly higher at 1.69 (95% CI  
0.87–3.27; p = 0.119) for subjects with the metabolic syndrome when  
compared with those with no metabolic abnormalities [61].  
Physical exercise ; 
Acute exercise 
Changes in the plasma fibrinogen levels have been reported after acute  
exercise, especially when post-exercise raw data were corrected for the  
contraction of plasma volume [64]. However, the results reported from various  
studies have been conflicting, due to differences in the populations studied,  
exercise protocols, testing procedures, and the analytical methods used for the  
assessment of plasma fibrinogen [65,66]. Moreover, whether exercise-induced  
blood hypercoagulability in vitro corresponds to in vivo thrombin generation  
and fibrin formation is unknown.  
Acute exercise may cause a rise in plasma fibrinogen levels in patients  
with some vascular disease states. For example, in patients with chronic AF  
exercised to exhaustion, plasma fibrinogen rose significantly within 20 minutes  
with a simultaneous alteration in fibrinolytic activity (i.e., reduced PAI) [67]. In  
another study, in patients with stable chronic heart failure exercised to  
exhaustion, plasma fibrinogen level increased significantly within 20 minutes  
[68]. These observations may contribute to the thromboembolic risk associated  
with these disease states.  
Regular exercise ; 
Regular exercise over a span of few weeks or months has shown a  
reduction in plasma fibrinogen levels both in healthy and diseased individuals.  
In healthy individuals, strenuous exercise over a period of 4 weeks  
lowers plasma fibrinogen levels, equivalent to a difference of about 15% in the  
risk of IHD [69]. In one study, a 12-week exercise-training programme in  
patients with mild hypertension resulted in a significant decrease in plasma  
fibrinogen and an improvement in overall coronary risk profile [65]. Regular  
physical exercise may also be beneficial in reducing overall coronary risk profile  
by decreasing the blood pressure and plasma fibrinogen levels in otherwise  
healthy individuals; Nevertheless, plasma fibrinogen levels return to baseline  
values after resumption of sedentary activity [70].  
Furthermore, in the Caerphilly Prospective Heart Disease Study [71],  
plasma fibrinogen concentrations were lowered by 0.24 g/l in the third of men  
who were the most active in leisure activities. Overall, the average decrease  
achieved by regular endurance exercise over several months was around 0.4  
g/l [72]. Men with low level of social activities and activities at home had a  
higher plasma fibrinogen concentration, when compared to those with high  
levels of activity [73].  
Therefore, the available evidence would suggest that regular exercise  
over a period could exert its beneficial influence on cardiovascular events  
through a beneficial effect on plasma fibrinogen levels.  
Seasonal differences ; 
Cardiovascular disorders, cerebrovascular disorders, associated risk  
factors and mortality all show a seasonal variation, with a peak during winter  
season, especially among the elderly. Correspondingly, plasma fibrinogen levels  
show a seasonal variation, with the peak in winter, both in normal healthy  
adults and in patients with cardiovascular disorders [74-78]. For example, the  
Rotterdam Study found a seasonal difference of 0.34 g/l (95% CI 0.29–0.39)  
and the difference was more pronounced in subjects aged 75 years or  
older[78]. In the latter group, the difference between winter and the summer  
months ranged as high as 23% [75].  
Seasonal variation in plasma fibrinogen levels with a rise in winter could  
be due partly to the observed seasonal variations in the known vascular risk  
factors, and partly to the factors described below.  
Vitamin C and infection ; 
It has been suggested that a lower dietary intake of vitamin C and/or an  
increase in upper respiratory infections (with its associated acute phase  
response) in the winter seasons might be the underlying cause for the raised  
levels of acute-phase reactants, especially fibrinogen. Furthermore, plasma  
fibrinogen levels correlate with various markers of respiratory infection, such  
as neutrophil count, C-reactive protein, self-reported cough and coryza[79].  
However, the studies have generally yielded inconsistent results [79-82].  
An increase in dietary vitamin C of 60 mg/day was associated with a  
decrease in plasma fibrinogen concentrations of 0.15 g/l, equivalent to a  
decline of approximately 10% in risk of IHD [80]. Nonetheless, it remains to be  
seen as to whether treatment of the infections results in decrease in plasma  
fibrinogen levels and whether decreasing the fibrinogen levels results in  
decreased cardiovascular morbidity and mortality.  
Organisms such as Chlamydia pneumoniae and Helicobacter pylori are  
implicated in the pathogenesis of coronary artery disease [83,84]. Fibrinogen  
may be implicated in the complex interaction of these infectious agents and  
coronary artery disease. Antibodies to C. pneumoniae are significantly  
increased in patients with stroke and severe essential hypertension, but there  
was no apparent association between these titres and plasma fibrinogen  
levels [82]. Fibrinogen is also thought to be an intermediary in the apparent  
link between H. pylori infection and coronary artery disease but once again,  
studies have yielded inconsistent results [84,85]. The recent STAMINA (South  
Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina) study  
showed that although antibiotic treatment failed to reduce plasma fibrinogen  
levels significantly, it significantly reduced adverse cardiac events in patients  
with acute coronary syndromes; however, the effect was independent of H.  
pylori or C. pneumoniae seropositivity [86]. Furthermore, in a recent meta- 
analysis of all published prospective studies, C. pneumoniae antibody titres  
were not predictive of CHD in the general population [87]. Therefore, the  
question of whether these infections increase the cardiovascular risk and if so,  
whether fibrinogen is an intermediary, is still far from clear.  
Psychosocial factors ; 
Adult plasma fibrinogen concentration is determined by various factors  
operating throughout life. The available data suggest that the inverse relation  
between socio-economic status and coronary artery disease may be partly  
explained by differences in plasma fibrinogen levels.  
In a cross-sectional study of civil servants in London, aged 45–55 years,  
measures of childhood environment (adult height, father’s social class, and  
participant’s education) were inversely associated with adult plasma fibrinogen  
concentration in both sexes [88]. Lower socio-economic status (as shown by  
employment grade) was also associated with higher plasma fibrinogen  
concentrations, which were not accounted for by measures of childhood  
circumstances. Control over work, assessed by personnel managers and self,  
was also inversely related to plasma fibrinogen levels [88].  
Furthermore, the results of the Stockholm Heart Epidemiology  
Programme (SHEEP) study suggest that adverse job characteristics might also  
be related to plasma fibrinogen concentrations, particularly in female  
workers [89]. Low self reported control over the job, inferred high demand,  
and inferred job strain were significantly associated with increased plasma  
fibrinogen concentration.  
Hormonal status ; 
Both cross sectional and longitudinal studies demonstrate that oral  
contraceptive (OC) pill use results in a significant rise in plasma fibrinogen  
levels, an effect that seems to be strongest in OCs with a high oestrogen  
concentration [90]. Furthermore, there are positive and significant interactions  
between OC use and smoking in their effects on haemostatic variables,  
including fibrinogen [91]. Conversely, plasma fibrinogen level returns to normal  
on discontinuation of the OC pill, usually within about 3 months [92].  
Both the menopausal status and HRT have independent effects on plasma  
fibrinogen levels [93]. The increases in factor VIIC, fibrinogen, and cholesterol  
levels with the menopause would increase the risk of fatal IHD in  
postmenopausal women by about 40%, compared with the risk in  
premenopausal women of the same age [94]. However, lower plasma viscosity  
and plasma fibrinogen levels are found in women on HRT (both with oestrogen- 
progesterone combinations and oestrogen monotherapy) [95]. Theoretically  
therefore, the use of HRT may exert a protective effect by reducing plasma  
fibrinogen levels.  
However, evidence for the influence of menopause and/or HRT on  
plasma fibrinogen has not been unequivocal. For example, Conard et al. (1997)  
reported a significant increase in plasma fibrinogen levels with oral oestrogen  
HRT [96]. Moreover, the only study on the effect of HRT on haemostatic factors  
following surgical menopause (patients aged 43 ± 6.5 years) did not find any  
significant difference in the levels of plasma fibrinogen among patients, prior  
to the surgery and following oopherectomy while taking HRT.  
Interestingly, in the Postmenopausal Estrogen/Progestin Interventions  
(PEPI) study, which was a three-year, double-blind, placebo-controlled trial of  
HRT on risk factors in 875 postmenopausal women, a lower baseline plasma  
fibrinogen level was significantly associated with venous thromboembolic  
events among subjects who subsequently received HRT [97].  
Many questions relating to the interaction between hormonal status,  
fibrinogen and cardiovascular disorders remain unanswered. The available data  
are inconsistent, and vary with regard to populations and type of hormone  
preparation studied.  
Smoking ; 
Available evidence suggests that cigarette smoking is strongly associated  
with increased plasma fibrinogen levels, and the adverse cardiovascular effects  
of smoking may partly be mediated through an increase in plasma fibrinogen  
levels [98-100]. Indeed, each cigarette smoked per day increases mean plasma  
fibrinogen by 0.35 g/l. [53]  
Similar data are available from epidemiological studies. In the  
Framingham study, plasma fibrinogen values were significantly higher in  
smokers than in non-smokers, with a dose-dependent increase with smoking in  
both sexes; ex-smokers had values as low as those of non-smokers. Over 10  
years of follow-up, the risk in both sexes increased progressively in relation to  
antecedent plasma fibrinogen values over the 1.8–4.5 g/l range [101]. In the  
second MONICA Augsburg survey, the impact on the population plasma  
fibrinogen level was most pronounced for age in both sexes, followed closely  
by body mass index and cigarette smoking [51]. In the MUNSTER Heart Study,  
smoking-related adverse changes in plasma fibrinogen were of greater  
magnitude in men than in women [102]. A switch from cigarette to cigar  
smoking is also associated with a large increase in plasma fibrinogen levels  
[103], in keeping with the observation that cigar smokers remain at an  
increased risk of IHD. [104]  
Passive smoking is not free of risk either, and may increase the risk of  
coronary heart disease partly by increasing plasma fibrinogen  
concentrations [105]. On average, plasma fibrinogen concentrations were 0.86  
g/l higher in women exposed to cigarette smoke outside the home and 1.12 g/l  
higher in women exposed both in and outside the home, when compared to  
women unexposed in either location. Thus, these effects of passive smoking  
were about 40–60% of that of current active smoking. Furthermore, smoking  
could have an acute effect on plasma fibrinogen levels. For example, post-MI  
patients who smoked within the previous 24 h had significantly higher plasma  
fibrinogen levels than patients who refrained from smoking for 24 h. [106]  
How does smoking alter plasma fibrinogen levels? Smoking results in an  
inflammatory reaction, probably of the pulmonary bronchi and alveoli and the  
blood vessels of the lung parenchyma, as evidenced by an increase in the levels  
of C-reactive protein [107,108]. The resulting inflammation may increase the  
production of the cytokines, such as interleukin-6 [109], which have major  
roles in the regulation of synthesis in the liver of acute-phase proteins,  
including fibrinogen [110,111]. Thus increased plasma fibrinogen levels in  
smokers may reflect a chronic inflammatory state of the vascular wall, and may  
act as an intermediary in the enhanced coronary risk among smokers.[112]  
Smoking potentiates thrombosis at the dysfunctional endothelium, at  
least partly by increasing the concentration of plasma fibrinogen and altering  
the activity of platelets. All these pro-atherogenic effects of smoking to injure  
the endothelium are also observed, albeit to lesser extent, in passive  
smokers. [113]  
Alcohol ; 
Moderate drinking appears to lower plasma fibrinogen concentrations.  
The so-called ‘French paradox’ may be at least partly explained in relation to  
the effects of alcohol on clotting factors. For example, in the DESIR Study  
(Data from an Epidemiological Study on the Insulin Resistance syndrome) of  
4967 men and women aged 30–64 years, alcohol consumption was associated  
with plasma fibrinogen levels, with higher concentrations in those who were  
non-drinkers or who drank > 60 g of alcohol per day. This U-shaped  
association was stronger amongst men than women. Consumption of wine and  
spirits was also associated with changes in plasma fibrinogen levels, whereas  
consumption of beer or cider was not. In women, for example, 1 g of alcohol  
per day induces a 0.008 g/l decrease in the mean plasma fibrinogen, while in  
men the decrease was 0.004 g/l within the down slope of the U-shaped  
curve. [53]  
These findings are further supported by other studies. For example, a U- 
shaped relation between alcohol consumption and plasma fibrinogen levels  
was also found in the second MONICA Augsburg survey (1989–1990),  
especially amongst men [51]. In the Scottish Heart Health Study, plasma  
fibrinogen was negatively associated with alcohol consumption in both  
sexes [114]. Nevertheless, as with other factors, there have been occasional  
reports of failure to correlate alcohol with plasma fibrinogen, as in the Munster  
Arteriosclerosis Study (MAS). [57]  
The precise mechanisms by which alcohol influences plasma fibrinogen  
levels remain uncertain. Animal experiments have suggested that alcohol  
exerts its effects through the action on the genetic expression of plasma  
fibrinogen in the liver cells [115]. On the other hand, alcohol can also result in  
high blood pressure and atrial fibrillation (AF), which are conditions associated  
with high plasma fibrinogen levels. [116,117]  
 Fibrinogen and CAD ; 
The concentration of plasma fibrinogen positively correlated with the  
severity of the underlying coronary heart disease in some studies [118-120].  
Plasma fibrinogen levels are higher in patients with unstable angina than in  
patients with stable angina, and higher in patients with severe vasospastic  
angina than in those with mild vasospastic angina and stable effort  
angina.[121,122]  
Nevertheless, a more recent study by Hoffmeister et al. failed to  
demonstrate a relationship between plasma fibrinogen levels and the severity  
of IHD in any of the three systems used to score the severity. [123]  
Furthermore, raised plasma fibrinogen levels have prognostic  
implications, being a strong predictor of coronary heart disease, fatal or non- 
fatal, new or recurrent, and of death from an unspecified cause, for both men  
and women [124-126], and therefore, a predictor of accelerated coronary  
atherosclerosis. Furthermore, the beneficial effect of statins and fibrates in  
reducing coronary artery diseases events and mortality cannot entirely be  
explained by their beneficial effect on lipids. In addition to lipid lowering, the  
modification of thrombus formation and degradation, alteration in  
inflammatory response, plaque stabilization and improved endothelial function  
are thought to be responsible for additional reduction of morbidity and  
mortality due to cardiovascular events [127]. Nonetheless, as explained below,  
although statins appear to improve thrombogenicity and endothelial dependent  
vasoresponsiveness, there is lack of convincing evidence of a reduction in  
plasma fibrinogen levels with statins, in contrast to the fibrates. For example,  
in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT), the  
beneficial effect of bezafibrate on coronary events in young male survivors of  
MI, was attributed partly to the reduction in plasma fibrinogen levels, in  
addition to the beneficial effect on plasma lipid profile. [128]  
Fibrinogen is also associated with other well-known risk factors for  
cardiovascular disease, such as smoking, age, obesity, hypertension and  
diabetes [129]. Elevation of plasma fibrinogen levels may therefore provide a  
mechanism for the risk factors to exert their effect. Certainly, the positive  
association between plasma fibrinogen levels and cardiovascular events is as  
strong as that for elevated cholesterol levels [130]. Higher levels of plasma  
fibrinogen markedly increase the predictive power of high serum LDL  
cholesterol; conversely, low plasma fibrinogen levels are associated with low  
coronary risk, even when LDL is raised [131]. Interestingly, plasma fibrinogen  
levels are also raised in people with family history of premature heart  
disease. Therefore, modification of cardiovascular risk factors may result in  
beneficial reduction of plasma fibrinogen levels and better cardiovascular  
outcome.  
FIBRINOGEN AND STROKE ; 
Several epidemiological studies have provided prospective data on plasma 
fibrinogen levels in relation to cardiovascular disease. According to these 
studies, the risk of developing a cardiovascular event such as IHD or stroke is 
1.8 to 4.1 times higher in subjects with fibrinogen levels in the top third than in 
those with levels in the lower third. Preliminary evidence also suggests that 
reducing fibrinogen levels in patients with high baseline levels and coronary 
disease may be beneficial.  
A meta-analysis of the six prospective epidemiological studies with 
samples representative of the general population, concluded that plasma 
fibrinogen was an independent cardiovascular risk factor, the results being 
uniform despite the diversity of study designs, sample compositions, follow-ups 
and end-point criteria. In this meta-analysis of 92 147 person-years experience, 
all prospective studies showed that plasma fibrinogen was associated with 
subsequent myocardial infarction (MI) or stroke. The odds ratio for the events in 
the upper vs. lower tertile varied between 1.8 (95% CI 1.2–2.5) in the 
Framingham study and 4.1 (95% CI 2.3–6.9) in the Gottingen risk incidence and 
prevalence study, with a summary odds ratio of 2.3 (95% CI 1.9–2.8). 
In another meta-analysis, which included 22 studies (13 prospective, 5 
cross-sectional, and 4 case-control) trying to determine the role of fibrinogen as 
a cardiovascular risk factor, the overall estimate of risk of cardiovascular events 
in subjects with plasma fibrinogen levels in the higher tertile, was twice as high 
as that of subjects in the lower tertile (OR 1.99; 95% CI 1.85–2.13). High 
plasma fibrinogen levels were associated with an increased risk of 
cardiovascular disease in healthy as much as in high-risk individuals. 
Fibrinogen Is a Marker for Nephropathy and 
Peripheral Vascular Disease in Type 1 Diabetes ; 
Fibrinogen levels were associated with nephropathy status in type 1  
diabetic subjects. In men but not women, there was a significant correlation  
between fibrinogen levels and albumin excretion rate across the entire range of  
albumin loss, with no evidence of a threshold for increased fibrinogen. In  
women, discontinuous analysis demonstrated that, whereas fibrinogen levels  
were similar in normoalbuminuric and microalbuminuric subgroups, there was  
a significant increase in plasma fibrinogen with macroalbuminuria. Therefore,  
in both men and women, fibrinogen was related to nephropathy as manifested  
by the severity of albuminuria. The results of previous studies in diabetic  
subjects have not been consistent and have shown varying associations  
between the presence of micro- and/or macroalbuminuria and elevated  
fibrinogen concentrations, most probably as a result of the varying influence of  
multiple additional factors and drug treatments. It is not clear, however,  
whether hyperfibrinogenemia occurs secondary to the onset of nephropathy or  
is a primary factor that antedates microalbuminuria. Further prospective  
evidence is required to confirm hyperfibrinogenemia as an independent  
predictor of future diabetic nephropathy. [132] 
Fibrinogen as an acute-phase reactant ; 
Plasma fibrinogen is an acute-phase protein, and is therefore likely to  
increase with inflammation or tissue necrosis. Interpretation of raised  
fibrinogen may be complicated by its behavior as an acute-phase reactant. For  
example, plasma fibrinogen concentrations are raised after acute stroke [133]  
and acute MI [134], probably as an acute phase response. Nevertheless,  
measurement of plasma fibrinogen levels could potentially be more useful than  
those of other acute phase reactants such as C-reactive protein, as fibrinogen is  
probably more specific to vascular disease.  
However, plasma fibrinogen strongly predicts cardiovascular events in  
patients with established atherosclerotic vascular disorders. Furthermore, it is  
raised even before the onset of acute stroke and acute MI in patients with  
transient ischaemic attack [135,136] and chronic stable angina pectoris [137]  
respectively. Therefore, though plasma fibrinogen is raised in the context of  
acute cerebrovascular and cardiovascular events, chronically raised plasma  
fibrinogen appears to be an independent risk factor for these events.  
Genetic variation in plasma fibrinogen ; 
Genetic variation in the fibrinogen gene may have implications in  
prognosis of patients with vascular disorders [138]. For example, the data from  
the Edinburgh Artery Study provide evidence that a polymorphism of the P  
fibrinogen gene is associated with a varying risk of peripheral atherosclerosis:  
the -455AA genotype was associated with over twice the risk of PAD, compared  
with the -455GG genotype.[139]  
Furthermore, in subjects with AF, Thr312Ala polymorphism gives rise to  
an increased susceptibility for embolization of intra-atrial clot, and there was  
decreased survival in those possessing the A allele following stroke,  
Similarly, in some patients with deep venous thrombosis, variations in the  
fibrinogen genotype could predispose to the embolization of formed fibrin clot,  
resulting in pulmonary embolism. [140] 
It is important to appreciate that although several studies demonstrate a  
strong association between polymorphisms of the fibrinogen ß-chain gene and  
plasma fibrinogen concentration, only a few have found a direct association  
between the former and the risk of ischaemic heart disease. A substantial  
number of studies failed to find an association between polymorphisms in the  
fibrinogen gene and cardiovascular risk [141-143]. For example, van der Bom  
et al. found that the -455G/A polymorphism was associated with increased  
plasma fibrinogen levels, but not with an increased risk for MI. These findings  
indicate that an increased plasma fibrinogen level due to this genetic factor  
may not increase the risk for MI. Similarly, Doggen et al. found that the TaqI,  
HaeIII and BclI polymorphisms in the fibrinogen gene were not associated  
with MI. [141] 
Therefore, many questions remain unanswered. Does a particular genetic  
polymorphism predispose to atherosclerotic disease? And if it does, is it  
mediated through raised fibrinogen or some associated mechanism? Some  
studies conducted on twins suggest that the environment, rather than genetic  
influences could have a greater influence on plasma fibrinogen levels. [144] 
Plasma Fibrinogen Levels in Lung Cancer ; 
In respect to the biological action of IL-6 in cancer patients, its direct  
effects on cancer cells have been observed [145,146], a  tumor-bearing state,  
however, the indirect function through the host inflammatory response cannot  
be disregarded. Among the acute-phase proteins induced by IL-6, fibrinogen  
been reported to be elevated in the plasma of patients with advanced cancer  
[147] involved in the growth of tumor tissue [149] as well as the inhibition of  
the cell-mediated immune response to cancer cells [150].  Fibrinogen levels,  
like IL-6 levels, were found to be elevated particularly in patients with  
advanced squamous cell or large cell carcinoma. Although the reason why no  
strong correlation was found between levels of IL-6 and fibrinogen remains  
undeter mined, it may be concerned in part with the preferential elevations of  
FDP level found in patients with elevated levels of both IL-6 and fibrinogen.  
This corresponds precisely to the  observations that plasma fibrinogen  
metabolism at the advanced stage of patients with solid cancer is diversely  
accelerated in both phases of production and degradable conversion to  
insoluble fibrin[147-149]. 
FIBRINOGEN AND HYPERTENSION ; 
In the Blue Mountains cohort of older Australians, in cross-sectional  
analysis, found that elevated plasma fibrinogen level was positively associated  
with prevalent hypertension both among men and women. In contrast, in  
prospective analysis, elevated plasma fibrinogen level was positively  
associated with 5-year incident hypertension among men but not women. This  
association was independent of smoking, alcohol intake, BMI, and other related  
factors. Among men, the OR of incident hypertension increased in a dose- 
dependent manner with increasing plasma fibrinogen  and the association was  
consistently present in subgroup analyses stratified by smoking, BMI, and JNC7  
BP categories. The findings from this long-term follow-up study of older,  
community-dwelling Australians are consistent with the recent observation  
reported by Folsom et al [151] suggesting a moderate positive association  
between plasma fibrinogen and incident hypertension among men but not  
among women in a middle-aged, biracial US cohort [152]. 
Fibrinogen and lipoprotein (a) ; 
A correlation between Fib and Lp(a) was not evident in smokers. This  
 
observation is not unexpected, because smoking increases the plasma levels of  
 
Fib [153,154] but does not influence serum Lp(a) [155,156].. The relationship  
 
between Fib and Lp(a) levels is indeed complex. It has been proposed that  
 
more than 90% of the variability in serum Lp(a) levels is genetically  
 
determined, [157] whereas this percentage is lower (30% to 50%) for Fib  
 
[158,159]. Nevertheless, impaired renal function, the menopause, and  
 
hypothyroidism can raise serum Lp(a) levels. Fibrinogen levels are higher in  
 
smokers, obese individuals, diabetic patients, and in women, especially after 
  
the menopause. Fibrinogen levels also rise with age. We eliminated some of  
 
this variability by considering subgroups and by excluding patients with  
 
diabetes, hypothyroidism, or impaired renal function and women taking  
 
hormone replacement therapy. And it propose that more extensive subclinical  
 
asymptomatic atherosclerosis tends to develop in subjects with largely  
 
genetically determined raised serum levels of Lp(a). This sequence of events  
 
may result in higher plasma Fib levels as a result of the inflammatory response  
 
associated with atherosclerosis [157]. This mechanism may, in part, account  
 
for the relationship between Fib and Lp(a). This hypothesis is supported by  
 
observation that the circulating levels of Lp(a) correlate with the extent of  
 
CVD;. Furthermore, the Fib–Lp(a) relationship may be influenced by a  
 
decrease in fibrinolytic activity caused by Lp(a). [157] 
 
Interventions to decrease plasma fibrinogen levels 
Beneficial Cessation of smoking 
 Medication: fibrates, doxazosin 
 Plasmapheresis 
 Moderate alcohol consumption 
May be beneficial Weight loss 
 Lowering blood pressure 
 Hormone replacement therapy 
Not beneficial Statins 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIM OF THE STUDY ; 
 
     Fibrinogen is a major determinant of plasma viscosity; an elevated 
 
fibrinogen level might also be associated with cardiovascular events. 
 
Whether the association between fibrinogen and cardiovascular events and  
 
whether fibrinogen predicts incidence of ischemic stroke is unclear. The aim  
 
of the study is to evaluate the fibrinogen levels in 50 patients with ischemic  
 
stroke and to determine the consistency of its association when compared  
 
with 50 patients without stroke as controls.  
 
 
MATERIALS AND METHODS; 
 
 
 This study was carried out in 50 patients who were admitted in the   
 
medical intensive care unit and intermediated care unit of PSG Hospitals,  
 
Coimbatore with a diagnosis of ischemic stroke between oct 2005 and 2007. 
 
 All patients were screened according to a protocol consisting of a  
 
complete medical history, neurological examination, standardized blood tests,   
 
CT scan of the brain or MRI, duplex scanning of the carotid arteries, and a  
 
cardiac analysis that included standard 12-lead ECG, transthoracic  
 
echocardiography and serum fibrinogen levels.  
 
 Cerebral infarction was defined as a focal neurological deficit of sudden  
 
onset that persisted beyond 24 hours in surviving patients, documented by a  
 
brain CT or an MRI indicating the presence of infarction or the absence of  
 
hemorrhage 
 
 Cerebrovascular risk factors such as never, current, or previous  
 
cigarette smoking; alcohol abuse (>100 g/d); hypercholesterolemia (history  
 
of hypercholesterolemia and/or fasting total cholesterol level >200 mg/dL);   
 
arterial hypertension (history of hypertension and/or systolic blood pressure  
 
>150 mm Hg and/or diastolic pressure >90 mm Hg); and diabetes mellitus  
 
(diagnosis according to the criteria of the National Diabetes Data Group )  
 
were screened together with associated medical diseases, left ventricular  
 
hypertrophy (as present when documented by standard 12-lead ECG),  
 
coronary heart disease (CHD; angina pectoris or previous Q and non-Q MI  
 
diagnosed by history, and peripheral arterial disease (PAD; in the presence of  
 
a history of intermittent claudication or previous arterial intervention or  
 
Doppler ultrasonography documentation). Routine laboratory investigations  
 
included a complete blood count, erythrocyte sedimentation rate, blood urea,  
 
creatinine, total cholesterol and  glucose, electrolytes, liver enzymes,  and  
 
plasma fibrinogen. Blood samples were taken  within 24 to 48 hours.  
 
      Analyses were adjusted for the effects of age at screening, sex, history of  
 
hypertension, diabetes,  smoking status, total cholesterol level, and body mass  
 
index. 
 
 
EXCLUSION CRITERIA ; 
 
1. Major renal, hepatic, and cancerous disease; 
 
2. Surgery or major trauma in the previous month; 
 
3. Obvious signs and clinical evidence of acquired inhospital infection; 
 
4. Past history of coronary artery disese; 
 5. old cerebrovascular accident. 
 
 
Determination of Plasma Fibrinogen Concentrations; 
 
 
      Blood was drawn as nonfasting samples participants into citrated tubes.  
 
Fibrinogen was measured by the clotting assay of Clauss . Mean values of  
 
fibrinogen were 2.76 g/L in our laboratory. Blood samples from cases were  
 
taken before administering heparin under aseptic precautions. 
 
 
Statistical analysis ; 
 
 It was perfomed using SPSS PC 11.5. Logistical regression in analysis  
 
was performed to find the effect of each variable. 
 
 
 
 
 
    
PROFORMA 
             
          S.NO : 
 
Sr. FIBRINOGEN LEVELS IN ACUTE ISCHEMIC STROKE 
 
Name :    Age:                            Address: 
 
IP.No :                                        Sex: 
 
DOA :                                        DOD: 
 
Presenting Complaints  :  
 
 
 
 
Significant Past History :  
                                                                                  Smokes  : Yes / No  
- DM                                                                   . Cigarettes/ Beedies  
- SHT                                                                  . No of Smoke :          /day  
- IHD                                                                  . Duration  : -  
- Previous MI / Stroke  
- Others  
 
General Examination : -  
 
               Pallor      : Yes / No                                                 Cyanosis        : Yes / No  
               Clubbing : Yes / No                                                 Pedal Edema : Yes / No  
                Vitals: -    Pulse:-            /  min                   Rhythm  :-   Peripheral pulses:-  
                                 BP    :             /           mm  hg  
 
Fundus Examintion  :-  
 
Carotids :-  
 
Central Nervous System of Examination :-  
 
Higher Mental Function :  
 
       Cranial Nerve  
       Motor System  
       Sensory System  
       Cerebellar  
        Others  
Examination of other system : -  
 
Investigations :- 
CBC:  
         RBC-                                                           RBS                -  
         HB  -                                                           UREA             - 
        WBC-                                                          Sr. Creat         -  
                  N       , L      , M       ,E     , B            FLP                  - 
 
        PLT -                                                           Urine Routine – 
 
        ESR –  
 
Sr. Fibrinogen  Level :-  
CXR              :-  
ECG              :-  
Echo              :-  
CV Doppler  : -  
CT Brain      : -  
MRI              :-  
Inferance      :-  
 
 
RESULT AND ANALYSIS ;  
 
Table – 1 
 
SERUM FIBRINOGEN LEVEL IN STUDY SUBJCTS 
 
NO AGE SEX SMOKING BMI CHOLES FIBRINOGEN 
in gms/l 
1 57 F  24.6 196 3.82 
2 43 F  22.9 154 3.57 
3 64 M YES 28.6 211 3.85 
4 47 M YES 21.4 254 4.22 
5 37 F  31.4 290 3.94 
6 67 M  20.6 174 4.28 
7 45 F  24.8 118 3.88 
8 59 M YES 23.1 182 3.84 
9 71 F  22.5 176 3.94 
10 53 F  25.8 294 3.6 
11 59 M  24.2 176 3.26 
12 51 M  27.8 154 3.83 
13 35 M YES 22.6 314 3.93 
14 61 F  23.8 196 4.02 
 
15 54 M  26.8 292 3.6 
16 64 M YES 24.1 258 4.02 
17 65 F  26.4 168 3.48 
18 47 M  26.2 272 4.14 
19 39 F  23.2 192 3.69 
20 56 F  24.6 256 4.2 
21 33 M  31.4 121 4.06 
22 62 M YES 21.7 118 3.88 
23 57 F  30.2 144 3.74 
24 49 M  28.4 182 4.28 
25 39 F  29.6 282 3.7 
26 61 F  19.6 168 4.22 
27 50 M YES 22.7 278 4.04 
28 72 F  20.1 116 4.42 
29 61 F  23.4 172 3.52 
30 36 F  29 234 3.75 
31 67 M YES 19.3 257 3.66 
32 55 F  27.4 278 3.78 
 
 
33 38 F  21.8 173 4.06 
34 58 M YES 26.7 246 4.68 
35 64 M YES 18 286 3.9 
36 68 F  26.8 190 3.54 
37 40 M  23.3 167 3.58 
38 61 F  32.1 341 4.86 
39 58 F  20.6 163 3.92 
40 51 M  28.9 316 4.52 
41 69 F  21.4 128 3.32 
42 39 F  27.8 186 3.81 
43 53 M  24.7 226 3.76 
44 63 F  22.7 152 3.12 
45 70 M YES 23.6 179 4.14 
46 45 F  26.7 187 4.04 
47 53 F  30.6 294 3.68 
48 37 F  23.6 151 4.16 
49 65 F  27.8 262 4.66 
50 55 M  24.7 176 3.7 
 
Table - 2 
 
SERUM FIBRINOGEN LEVEL IN CONTROL GROUP 
 
 
NO AGE SEX SMOKING BMI CHOLES FIBRINOGEN 
in gms/l 
1 35 M YES 23.4 186 2.94 
2 39 F  24.6 265 2.68 
3 39 F  30.6 294 3.14 
4 36 F  26.4 157 3.02 
5 34 M YES 20.6 256 2.16 
6 38 F  28.7 183 2.7 
7 37 M  31.3 146 2.66 
8 38 F  31.7 194 2.86 
9 40 M YES 29.1 213 2.68 
10 55 F  24.8 196 3.12 
11 59 M  27.4 126 2.16 
12 53 F YES 22.7 164 3.48 
13 47 M  31.2 310 2.02 
14 55 F  30.3 188 2.86 
15 55 M  28.6 152 2.84 
16 51 F YES 22.4 272 3.76 
17 48 F  21.6 164 2.28 
18 57 F  27.2 282 2.58 
19 52 M YES 23.8 114 2.42 
20 49 F  23.2 273 2.32 
21 53 M  23.5 136 2.26 
22 59 F  29.4 242 2.64 
23 45 M YES 23.3 304 3.92 
24 51 M YES 22.4 167 2.78 
25 59 F  30.8 308 2.76 
26 57 M YES 24.3 297 2.88 
27 60 F  24.6 174 2.14 
28 56 M YES 23.4 214 2.52 
29 49 F  29.8 276 2.69 
30 50 M YES 31.2 106 2.26 
31 51 F  31.4 136 2.66 
32 57 M YES 25.8 245 2.46 
33 49 M YES 23.5 264 2.58 
34 67 F  24.2 192 2.92 
35 70 M  25.6 289 2.7 
36 63 F  22.2 174 2.58 
37 65 M YES 19.6 182 2.72 
38 71 F  27.6 314 3.16 
39 61 M  24 146 2.36 
40 68 M  22.8 226 2.72 
41 65 M YES 22.4 212 2.78 
42 61 F  18.9 278 2.26 
43 61 M YES 20.4 178 2.48 
44 67 F  28.4 266 2.54 
45 63 M  31.5 347 2.28 
46 66 M YES 26.6 246 4.06 
47 70 F  29.2 194 2.84 
48 68 M  23.4 256 2.9 
49 69 F  28.2 247 2.78 
50 63 M  24.1 182 2.62 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION ; 
 
 Between October 2005 – 07 patients with clinical signs attributable to  
 
ischemic stroke were identified. After comprehensive evaluation, 50 patients  
 
were included. 
 
 Among 50 patients included in the derivation set there were 22 men and  
 
28 women. The mean age was 54.06. A greater prevalence of fibrinogen level  
 
and between male sex (mean – 3.96) was noted..  
 
 The mean level of fibrinogen obtained in patients with stroke was 3.91  
 
gms/l and the control group was 2.71 gms/l in our study. On comparing both  
 
the groups t – test was performed and the difference were found to be  
 
statistically significant. ( odds ratio – 272.332, 95% CI between 32.76 and  
 
2263.7, p value < .001). In this study we found that serum fibrinogen level is  
 
significantly higher in patients with ischemic stroke compared to controls. 
 
 
 
SERUM FIBRINIGEN LEVELS IN GMS/L  IN STUDY AND 
CONTROL GROUP ; TABLE - III 
 
 TOTAL NO SUBJECTS MEAN 
STUDY GROUP 50 3.91 
CONTROL  GROUP 50 2.71 
 
 
 John Danesh et al in their meta analysis, included individual participant  
 
data from 31 prospective studies of major cardiovascular diseases and  
 
nonvascular mortality among 154211 individuals without known  
 
cardiovascular diseases at baseline. It provides the first reliable demonstration  
 
that fibrinogen is associated with the age specific incidence rates of CHD,  
 
stroke, other vascular mortality and interestingly, of the aggregate of all  
 
nonvascular causes. This meta analysis also indicates that the association of  
 
fibrinogen with CHD, stroke do not differ substantially by baseline levels of  
 
established risk factors. [160]  
 
 Sckakibara and collegues in their study, found out that plasma fibrinogen  
 
levels are correlated with conventional cardiovascular risk factors even after  
 
adjusting for the CRP levels. [161]        
 
 Sinning JM et all conducted a substudy of the prospective AtheroGene  
 
registry, assessed in 1806 patients with documented CAD and stable angina  
 
pectoris, the risk of cardiovascular death and non-fatal myocardial infarction  
 
(n=183) over a median follow-up of 3.5 (maximum 7.7) years according to  
 
baseline levels of C-reactive protein and fibrinogen and found out that in  
 
patients with documented CAD, C-reactive protein and fibrinogen were  
 
predictive for future cardiovascular risk. [161] 
 
 In one study conducted in 2632 subjects from cycle 5 of Framingham  
 
offspring population further characterize the association between fibrinogen  
 
and cardiovascular disease. [163] 
 
 Schila sabeti and collegues assessed serum fibrinogen levels without  
 
recent cerebrovascular diseases in 1268 patients, found that although  
 
fibrinogen cannot be referred to as an independent risk predictor, it still may  
 
be worth considering as an indicator for progressive atherosclerosis and  
 
potentially for the occurrence of future neurological complications. [164]                      
 
 Large population based studies such as COPENHAGEN CITY STUDY               
 
( n = 8755 ) and the GOTHENBURG study (n = 792 ) unequivocally  
 
demonstrated an increasing risk for stroke with increasing levels of fibrinogen,  
 
suggesting that fibrinogen may be worh investigating further with respect to  
 
its role in cerebrovascular disease. 
 
 EUROSTROKE is a collaborative project among ongoing European cohort  
 
studies. This analysis on the Eurostroke project indicates that fibrinogen is a  
 
powerful indicator for stroke. 
 
In the Leigh General Practice Study, 505 men aged 40–69 years and free  
 
from IHD, diabetes and hypertension were recruited from one general practice  
 
in the UK. After a mean follow-up of 7.3 years, 40 cases of MI occurred. On  
 
multivariate analysis, plasma fibrinogen proved to be the strongest predictor of  
 
adverse cardiovascular events 
 
 One more prospective trial for 13.5 yrs conducted by wilhelmsen and  
 
colleagues proved the possibility of serum fibrinogen to play an important part  
 
in the development of stroke and MI. 
 
 
 However there have been few studies which demonstrated no relation  
 
between serum fibrinogen levels and stroke, to quote a few studies… 
 
 Peter M . Rothudi et al estimated fibrinogen concentration and risk of  
 
ischemic stroke and acute coronary events in 5113 patients and concluded  
 
there was no significant heterogenicity in fibrinogen risk associations. 
 
 Schinichi sabo et all studied the association of serum fibrinogen  
 
concentration with stroke in 4608 men and 7589 women and did not find a  
 
positive association between fibrinogen and risk of ischemic stroke. [165] 
         
 This finding was consistant with the result of ARIC study showing a  
 
positive association of fibrinogen with risk of coronary heart disease but not of  
 
ischemic stroke. 
 
 However to find out in totality whether serum fibrinogen is an  
 
independent risk factor or not, many studies with large number of subjects  
 
with proper inclusion and exclusion criteria will have to be conducted to come  
 to a final definite conclusion.  
 
 In our study there is a positive correlation between fibrinogen levels and  
 
smoking was found out. Similar data are available from epidemiological  
 
studies. In the Framingham study, plasma fibrinogen values were significantly  
 
higher in smokers than in non-smokers, with a dose-dependent increase with  
 
smoking in both sexes; ex-smokers had values as low as those of non-smokers.  
 
 In the second MONICA Augsburg survey, the impact on the  
 
population plasma fibrinogen level was most pronounced for age in both sexes,  
 
followed closely by body mass index and cigarette smoking [51]. In the  
 
MUNSTER Heart Study, smoking-related adverse changes in plasma fibrinogen  
 
were of greater magnitude in men than in women [102]. A switch from  
 
cigarette to cigar smoking is also associated with a large increase in plasma  
 
fibrinogen levels [103], in keeping with the observation that cigar smokers  
 
remain at an increased risk of IHD [104].  
 
 But there is no significant two way interaction between fibrinogen and  
 two other risk factors, serum total cholesterol and BMI in our study. ( p >  
 
.001). Baseline total cholesterol and body mass index were compared in cases  
 
and controls. Mean total cholesterol level was lower in cases than in controls.  
 
And there was no significant relationship between total cholesterol and the risk  
 
of ischemic stroke in this study. (95% CI .991-101.004). 
 
 Carrole L Hart et al analysed all the risk factors for stroke using 7052  
 
men and 8354 women prospectively for 20 years. In this study it was found to  
 
be no relationship  between total cholesterol and stroke.[166]     
 
 Tom hoslen in his study found out that a higher cholesterol favours  
 
development of minor strokes and major strokes are often seen in patients  
 
with lower cholesterol levels.                         
 
 
 The role of cholesterol in stroke is unclear. Most prospective studies have  
 
failed to find a definite relation between total cholesterol level and the risk of  
 
stroke. This finding is consistent with the findings from the Copenhagen Study  
 
[167]. Despite the lack of association between serum total cholesterol and risk  
 
of stroke in observational epidemiological studies, the results of lipid-lowering  
 
trials with statin agents suggest benefit for stroke reduction [168-170]. It has  
 
been suggested that the beneficial effects of statins on clinical events may  
 
involve mechanisms independent of lipid-lowering such as modification of  
 
endothelial function, inflammatory responses, plaque stability, and thrombus  
 
formation. [171]  
 
 Encouragingly, plasma fibrinogen is partly a modifiable risk factor, and  
 
suitable lifestyle changes usually result in favourable decreases in plasma  
 
fibrinogen levels, although drug therapy has not been fully validated. In one  
 
trial conducted by M. Lin et al included five trials involving 2926 patients, and  
 
found out that fibrinogen depleting agents moderately reduce the proportion of  
 
patients who were dead or disabled. Several drugs are known to reduce the  
 
fibrinogen levels, including bezafibrate, beta blockers, pentoxifylline and  
 
ticlopidine [172,173]. Moreover lifestyle modification, including smoking  
 
cessation and increased exercise can reduce fibrinogen levels. [174]. However  
 
more data, particularly ESTAT data, are needed before more reliable  
 
conclusions can be drawn. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY AND CONCLUSION ; 
 
 This study was carried out on 50 subjects who presented with ischemic  
 
stroke and got admitted in the medical intensive care unit between oct 2005 –  
 
07.  Serum fibrinogen level was estimated by using clauss method. 
  
 The mean level of fibrinogen obtained in patients with stroke was 3.91  
 
gms/l and the control group was 2.71 gms/l in our study. In this study we  
 
found that serum fibrinogen level is significantly higher in patients with  
 
ischemic stroke compared to controls. . ( odds ratio – 272.332, 95% CI  
 
between 32.76 and 2263.7, p value < .001). Serum fibrinogen level in this  
 
study was found to be an important risk factor in ischemic stroke. 
 
Literature review in connection with the study revealed many studies  
 
which demonstrated the independent effects of increased fibrinogen level as  
 
one of the risk factor for ischemic stroke.  
 
A definite association exists between fibrinogen and  
 
atherothrombogenesis. However, the nature of the link is unclear. Although  
 
epidemiological and clinical studies suggest that the link is causal, no definite  
 
evidence exists. It appears that fibrinogen concentration and plasma viscosity  
 
are at least as predictive of coronary events as are cholesterol concentration,  
 
diastolic blood pressure and body mass index. 
Encouragingly, plasma fibrinogen is partly a modifiable risk factor, and  
suitable lifestyle changes usually result in favourable decreases in plasma  
fibrinogen levels, although drug therapy has not been fully validated.  
The relationship between genetic polymorphism in the fibrinogen gene  
and cardiovascular risk is very complex. Although polymorphisms in the  
fibrinogen gene could potentially augment the cardiovascular risk through  
increased fibrinogen levels, the effect appears to be antagonized by some  
unknown mechanism due to the same polymorphism. Therefore,  
polymorphisms of fibrinogen gene may modify the effect of external influences  
on the final phenotype (i.e. the vascular risk) rather than directly affecting the  
risk of the disease through plasma fibrinogen levels. In future, gene- 
environment interactions should be considered in evaluating the relevance of  
genetic variations on the risk of cardiovascular disease 
Future directions require determination of the ‘critically elevated’  
 
fibrinogen threshold value, development of drugs that would specifically and  
 safely decrease plasma fibrinogen levels and conduction of interventional trials  
 
to study the influence of lowering fibrinogen levels on overall cardiovascular  
 
risk profile. 
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